observed primarily in patients with moderate (score 2) to mild (score 1) manifestations. It is noteworthy that 6 of 11 manifestations with a score 2 responded to rituximab therapy. Improvement in the skin, mouth, eye, liver, joints and fascia, intestine, and serous membrane was observed in 2 of 7, 1 of 5, 1 of 4, 1 of 1, 1 of 4, 0 of 1, and 0 of 1 cases, respectively. Notably, all cases of immune thrombocytopenia and anemia were responded well to rituximab. However, PS improved only in 1 patient who achieved a PR.

3.4 Immunological monitoring

B cell numbers were monitored after rituximab therapy using a flowcytometric analysis. CD19$^+$ B cells were quickly eliminated within 2 weeks after the first treatment and did not repopulate at least by 12 weeks (Fig. 1). Serum levels of IgG and IgA were unchanged by 6 weeks, but gradually declined thereafter. Serum IgM levels decreased much earlier and more profound compared with those of IgG and IgA.

4 Discussion

The prognosis of corticosteroid-refractory chronic GVHD is poor, and no standard therapy for corticosteroid-refractory chronic GVHD is available [1, 3]. In the present study, we evaluated the efficacy and safety of rituximab therapy in patients with quiescent-type chronic GVHD. This condition may have been related to the ethnicity of the transplant patients. The incidence of progressive-type chronic GVHD is high, reportedly 10–70% in Western countries [24, 25]. In contrast, progressive-type GVHD is rare and quiescent-type GVHD is common in Japanese patients [22]. Rituximab therapy was well tolerated, and no severe adverse events were attributed to rituximab therapy. A 4-week course of rituximab treatment produced an overall response rate of 43% at 1 year, which is slightly lower than

Fig. 1 Laboratory parameters over time after rituximab therapy. IgG, IgA and IgM levels are shown as percentage of baseline levels.*$P < 0.01$ compared with IgG or IgA

the overall response rate of 50–83% reported in previous studies testing the efficacy of rituximab [11–13, 15–17]. CR rates ranged from 0 to 20% in previous studies [12, 13, 16, 17]. In the present study, none of the patients achieved CR. The steroid-sparing effect is an important indicator of efficacy assessments of GVHD [26]. Rituximab therapy resulted in a median reduction in the dose of corticosteroids of 67%, which was slightly lower than the 75–86% reduction in dose observed in 3 previous studies that addressed the steroid-sparing effect of rituximab in this setting [13, 15, 16]. These results were surprising because we initially hypothesized that rituximab would be more effective in Japanese patients who tend to develop less severe chronic GVHD than Caucasians [22].

Previous studies of the efficacy of rituximab therapy for steroid-resistant chronic GVHD highlight the potential activity of rituximab against skin involvement, including scleroderma, whereas the responses to rituximab appear to be less pronounced in other organs or tissues [11–17]. These studies also suggested that the steroid-sparing effect might be more pronounced in the skin and oral lesions than others in chronic GVHD [15, 16]. In addition, hematologic abnormalities associated with chronic GVHD also respond well to rituximab therapy [11, 15, 27]. In our study, rituximab was most effective against immune thrombocytopenia and AIHA, and less effective against skin sclerosis and joint contracture related to sclerodermatous skin lesions and fascitis. This discrepancy between the current study and previous studies might have resulted because more patients with advanced sclerodermatous chronic GVHD were enrolled in our study than in the previous studies. The interval between the time of the onset of chronic GVHD and the time of study enrollment was longer in the present study (median duration 37 months) than in most of the previous studies (median duration 14–37 months) [11–13, 15, 17]. Nonetheless, our patients had undergone less immunosuppressive therapy before study enrollment than did the patients in the previous studies, most of whom had received multiple courses of immunosuppressive therapy [11, 12, 15]. Thus, the long-term duration of disease without sufficient intervention might have resulted in the development of irreversible damage in our patients.

Many advanced manifestations in chronic GVHD are potentially irreversible, including skin and joint contracture, chronic dry eye, esophageal and vaginal stricture, and bronchiolitis obliterans in the lung. The enrollment of patients with advanced chronic GVHD may not be appropriate when the endpoint of the study is the response to treatment. Alternatively, irreversible lesions could be excluded from consideration in the assessment of response [28, 29]. Such considerations were not specified in our protocol. The results of our study suggest that rituximab

may be more effective against mild to moderate manifestations than against severe manifestations of chronic GVHD. Thus, earlier treatment with rituximab or with other investigational agents for corticosteroid-refractory chronic GVHD may increase the chances of a good response. Another possible explanation for the poorer response to rituximab in our study than in previous studies, although unlikely, is that dominant immunological mechanisms associated with chronic GVHD and treatment outcomes may differ by ethnicity, because the prognostic scoring system [25], which was developed on the basis of clinical findings in Western patients, is not prognostic in Japanese patients [22].

We confirmed complete depletion of B cells after rituximab therapy. B cells were still absent 2 months after the last infusion of rituximab. In the initial multi-institutional trial evaluating a single four dose course of rituximab in patients with follicular lymphoma, the median B cell count did decline to almost undetectable levels after the first dose in the majority of patients, with recovery beginning from 6 to 9 months post-treatment, and return to normal levels between 9 and 12 months [30]. Similarly, B cells were undetectable in patients with chronic GVHD until 1 year after rituximab therapy [13]. Such a profound and prolonged B cell depletion may explain why rituximab treatment is effective in several antibody-mediated autoimmune diseases with some responses ongoing for more than 1–2 years [31]. On the other hand, rituximab therapy could results in impaired humoral immune responsiveness [32]. We also found that serum immunoglobulin levels decrease after rituximab therapy. Of note, IgM fell much more than IgG and IgA. This phenomenon was observed in patients with rheumatoid arthritis and chronic GVHD [13, 33]. This may be due to higher sensitivity of IgD$^+$ memory B cell subset, which produces natural mutated IgM antibodies as a first-line of defense against blood-borne antigens [33, 34], to rituximab than plasma cells.

In conclusion, the current study suggests that rituximab therapy may be effective for selective patients with corticosteroid-refractory chronic GVHD that is not advanced. A recent study indicated that that low-dose rituximab therapy is also effective [17]. However, the optimal schedule and dosing regimens for rituximab need to be determined. Furthermore, a well-designed, large-scale, prospective study is needed to conclusively address the efficacy of rituximab in the treatment of corticosteroid-refractory chronic GVHD.

References

1. Lee SJ, Vogelsang G, Flowers ME. Chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2003;9:215–33.
2. Filipovich AH, Weisdorf D, Pavletic S, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant. 2005;11:945–56.
3. Arora M, Burns LJ, Davies SM, et al. Chronic graft-versus-host disease: a prospective cohort study. Biol Blood Marrow Transplant. 2003;9:38–45.
4. Chu YW, Gress RE. Murine models of chronic graft-versus-host disease: insights and unresolved issues. Biol Blood Marrow Transplant. 2008;14:365–78.
5. Teshima T, Wynn T, Soiffer R, Matsuoka K-I, Martin P. Chronic graft-versus-host disease: how can we release Prometheus? Biol Blood Marrow Transplant. 2008;14:142–50.
6. She K, Gilman AL, Aslanian S, et al. Altered Toll-like receptor 9 responses in circulating B cells at the onset of extensive chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2007; 13:386–97.
7. Miklos DB, Kim HT, Zorn E, et al. Antibody response to DBY minor histocompatibility antigen is induced after allogeneic stem cell transplantation and in healthy female donors. Blood. 2004;103:353–9.
8. Miklos DB, Kim HT, Miller KH, et al. Antibody responses to H–Y minor histocompatibility antigens correlate with chronic graft-versus-host disease and disease remission. Blood. 2005;105: 2973–8.
9. Zorn E, Miklos DB, Floyd BH, et al. Minor histocompatibility antigen DBY elicits a coordinated B and T cell response after allogeneic stem cell transplantation. J Exp Med. 2004;199:1133–42.
10. Zhang C, Todorov I, Zhang Z, et al. Donor CD4+T and B cells in transplants induce chronic graft-versus-host disease with autoimmune manifestations. Blood. 2006;107:2993–3001.
11. Ratanatharathorn V, Carson E, Reynolds C, et al. Anti-CD20 chimeric monoclonal antibody treatment of refractory immune-mediated thrombocytopenia in a patient with chronic graft-versus-host disease. Ann Intern Med. 2000;133:275–9.
12. Canninga-van Dijk MR, van der Straaten HM, Fijnheer R, Sanders CJ, van den Tweel JG, Verdonck LF. Anti-CD20 monoclonal antibody treatment in 6 patients with therapy-refractory chronic graft-versus-host disease. Blood. 2004;104:2603–6.
13. Cutler C, Miklos D, Kim HT, et al. Rituximab for steroid-refractory chronic graft-versus-host disease. Blood. 2006;108: 756–62.
14. Okamoto M, Okano A, Akamatsu S, et al. Rituximab is effective for steroid-refractory sclerodermatous chronic graft-versus-host disease. Leukemia. 2006;20:172–3.
15. Zaja F, Bacigalupo A, Patriarca F, et al. Treatment of refractory chronic GVHD with rituximab: a GITMO study. Bone Marrow Transplant. 2007;40:273–7.
16. Mohty M, Marchetti N, El-Cheikh J, Faucher C, Furst S, Blaise D. Rituximab as salvage therapy for refractory chronic GVHD. Bone Marrow Transplant. 2008;41:909–11.
17. von Bonin M, Oelschlagel U, Radke J, et al. Treatment of chronic steroid-refractory graft-versus-host disease with low-dose rituximab. Transplantation. 2008;86:875–9.
18. Oh H, Loberiza FR Jr, Zhang MJ, et al. Comparison of graft-versus-host-disease and survival after HLA-identical sibling bone marrow transplantation in ethnic populations. Blood. 2005;105: 1408–16.

19. Morishima Y, Morishita Y, Tanimoto M, et al. Low incidence of acute graft-versus-host disease by the administration of methotrexate and cyclosporine in Japanese leukemia patients after bone marrow transplantation from human leukocyte antigen compatible siblings; possible role of genetic homogeneity. The Nagoya Bone Marrow Transplantation Group. Blood. 1989;74:2252–6.

20. Morishima Y, Kodera Y, Hirabayashi N, et al. Low incidence of acute GVHD in patients transplanted with marrow from HLA-A, B, DR-compatible unrelated donors among Japanese. Bone Marrow Transplant. 1995;15:235–9.

21. Sasazuki T, Juji T, Morishima Y, et al. Effect of matching of class I HLA alleles on clinical outcome after transplantation of hematopoietic stem cells from an unrelated donor. Japan Marrow Donor Program. N Engl J Med. 1998;339:1177–85.

22. Atsuta Y, Suzuki R, Yamamoto K, et al. Risk and prognostic factors for Japanese patients with chronic graft-versus-host disease after bone marrow transplantation. Bone Marrow Transplant. 2006;37:289–96.

23. Shulman HM, Sullivan KM, Weiden PL, et al. Chronic graft-versus-host syndrome in man: a long-term clinicopathologic study of 20 Seattle patients. Am J Med. 1980;69:204–17.

24. Lee SJ, Klein JP, Barrett AJ, et al. Severity of chronic graft-versus-host disease: association with treatment-related mortality and relapse. Blood. 2002;100:406–14.

25. Akpek G, Lee SJ, Flowers ME, et al. Performance of a new clinical grading system for chronic graft-versus-host disease: a multicenter study. Blood. 2003;102:802–9.

26. Martin PJ, Storer BE, Rowley SD, et al. Evaluation of mycophenolate mofetil for initial treatment of chronic graft-versus-host disease. Blood. 2009;113:5074–82.

27. Ratanatharathorn V, Ayash L, Reynolds C, et al. Treatment of chronic graft-versus-host disease with anti-CD20 chimeric monoclonal antibody. Biol Blood Marrow Transplant. 2003;9:505–11.

28. Pavletic SZ, Martin P, Lee SJ, et al. Measuring therapeutic response in chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. Response Criteria Working Group report. Biol Blood Marrow Transplant. 2006;12:252–66.

29. Martin PJ, Weisdorf D, Przepiorka D, et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: VI. Design of Clinical Trials Working Group Report. Biol Blood Marrow Transplant. 2006;12:491–505.

30. McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol. 1998;16:2825–33.

31. Parodi E, Nobili B, Perrotta S, et al. Rituximab (anti-CD20 monoclonal antibody) in children with chronic refractory symptomatic immune thrombocytopenic purpura: efficacy and safety of treatment. Int J Hematol. 2006;84:48–53.

32. van der Kolk LE, Baars JW, Prins MH, van Oers MH. Rituximab treatment results in impaired secondary humoral immune responsiveness. Blood. 2002;100:2257–9.

33. Roll P, Dorner T, Tony HP. Anti-CD20 therapy in patients with rheumatoid arthritis: predictors of response and B cell subset regeneration after repeated treatment. Arthritis Rheum. 2008;58:1566–75.

34. Weller S, Braun MC, Tan BK, et al. Human blood IgM "memory" B cells are circulating splenic marginal zone B cells harboring a prediversified immunoglobulin repertoire. Blood. 2004;104:3647–54.

Possible Association between Obesity and Posttransplantation Complications Including Infectious Diseases and Acute Graft-versus-Host Disease

Shigeo Fuji,[1] Sung-Won Kim,[1] Ken-ichi Yoshimura,[2] Hideki Akiyama,[3] Shin-ichiro Okamoto,[4] Hiroshi Sao,[5] Junko Takita,[6] Naoki Kobayashi,[7] Shin-ichiro Mori[1] for the Japan Marrow Donor Program

Both obesity and malnutrition are considered risk factors for complications after bone marrow transplantation (BMT). To elucidate the impact of pretransplantation body mass index (BMI) on clinical outcome, we performed a retrospective cohort study with registration data from the Japan Marrow Donor Program (JMDP). Between January 1998 and December 2005, a total of 3935 patients received unrelated BMT through the JMDP; of these, 3827 patients for whom pretransplantation height and weight data were available were included in the study. Patients were stratified according to pretransplantation BMI values (low BMI: BMI < 18 kg/m^2, n = 295; normal BMI: $18 \le$ BMI < 25 kg/m^2, n = 2906; overweight: $25 \le$ BMI <30 kg/m^2, n = 565; obese: 30 kg/m$^2 \le$ BMI, n = 61). In a univariate analysis, pretransplantation BMI was associated with a significantly greater risk of grade II-IV acute graft-versus-host disease (GVHD; $P = .03$). Multivariate analysis showed that pretransplantation BMI tended to be associated with an increased risk of grade II-IV acute GVHD ($P = .07$). Obesity was associated with an increased risk of infection compared with normal BMI (odds ratio = 1.9; 95% confidence interval = 1.1 to 3.2; $P = .02$). Our findings demonstrate a correlation between pretransplantation BMI and posttransplantation complications. Although BMI depends strongly on multiple factors, the effect of obesity on clinical outcome should be evaluated in a prospective study.

Biol Blood Marrow Transplant 15: 73-82 (2009) © 2009 American Society for Blood and Marrow Transplantation

KEY WORDS: Obesity, Allogeneic transplantation, Infection, Acute graft-versus-host disease

INTRODUCTION

Both obesity and malnutrition are considered risk factors for complications and increased relapse and

From the [1]Department of Hematology and Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan; [2]Department of Clinical Trial Management, Translational Research Center, Kyoto University Hospital, Kyoto, Japan; [3]Department of Hematology, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan; [4]Division of Hematology, Department of Medicine, Keio University School of Medicine, Tokyo, Japan; [5]Department of Hematology, Meitetsu Hospital, Nagoya, Japan; [6]Department of Pediatrics, Graduate School of Medicine, University of Tokyo, Tokyo, Japan; and [7]Department of Hematology, Sapporo Hokuyu Hospital, Sapporo, Japan.

nonrelapse mortality in hematopoietic stem cell transplantation (HSCT). An inferior outcome after allogeneic HSCT has been reported in obese adult patients in both allogeneic [1,2] and autologous HSCT [3-5]. Furthermore, our group recently reported that hyperglycemia during the neutropenic period is associated with an increased risk of acute graft-versus-host disease (GVHD) and subsequent nonrelapse mortality [6]. Obesity obviously is associated with an increased risk of hyperglycemia [7], which can lead to an inferior outcome after allogeneic HSCT. Recently, obesity was reported to be associated with low-grade systemic inflammation and was identified as a possible risk factor for autoimmune diseases [8-10]. Alternatively, malnutrition has been reported to be associated with an increased risk of early death after allogeneic HSCT [11,12]. Several reports have noted an association between malnutrition and a high incidence of infectious disease in conventional chemotherapy settings [13-15].

Although we can speculate that these infectious complications may be associated with nonrelapse mortality in HSCT, there is currently no agreement

73

regarding a suitable target range of pretransplantation body mass index (BMI) for clinical management. Previous studies have included various kinds of stem cell sources, and some have included HSCT with T cell depletion. The aim of the present study was to retrospectively evaluate the impact of pretransplantation BMI on the clinical outcome after unrelated bone marrow transplantation (BMT) for hematologic malignancies, using registration data from the Japan Marrow Donor Program (JMDP). The results should provide insight into how to better manage nutritional support for patients undergoing HSCT.

PATIENTS AND METHODS

A total of 3935 patients with various hematologic malignancies underwent BMT through the JMDP between January 1998 and December 2005. Data from 3827 of these patients for whom pretransplantation height and weight data were available were included in the present study. Patient characteristics are summarized in Table 1. The median patient age was 39 years (range, 18 to 72 years), and diagnoses included acute myeloid leukemia (AML; n = 1165), acute lymphoblastic leukemia (ALL; n = 755), myelodysplastic syndrome/myeloproliferative disease (MDS/MPD; n = 597), malignant lymphoma (ML; n = 500) and chronic ML (CML; n = 576), other leukemia (n = 69), multiple myeloma (n = 71), and other (n = 94). Standard risk included acute leukemia in first complete remission (CR1), CML in first chronic phase, MDS in refractory anemia, and lymphoma in CR1. The rest of the patients were categorized as a high-risk group. Bone marrow was the sole stem cell source for transplantation. Total body irradiation (TBI) was used in 2849 patients. GVHD prophylaxis included cyclosporine (CSP)-based (n = 1520) and tacrolimus (TAC)-based regimens (n = 2155), or other combinations (n = 152), with the addition of low-dose antithymocyte globulin (ATG) in 205 patients. Alleles at the HLA-A, -B, and -DRB1 loci were identified by high-resolution DNA typing. The median follow-up period was 565 days. Informed consent was obtained from patients and donors in accordance with the Declaration of Helsinki, and the study design was approved by the JMDP's Institutional Review Board.

The study's primary endpoints were nonrelapse mortality at 100 days and 1 year, overall survival at 1 year, and progression-free survival at 1 year. For nonrelapse mortality, an event was death without disease progression after BMT. For overall survival, an event was death from any cause after BMT. For progression-free survival, an event was disease progression or death after BMT. Secondary endpoints were the incidence of infection (bacterial, viral, fungal, and others); incidence of lung organ toxicity including

interstitial pneumonia, adult respiratory distress syndrome, bronchiolitis obliterans, pulmonary hemorrhage, and others, excluding pneumonia with obvious infectious diseases; and incidence of hepatic toxicity, including veno-occlusive disease and drug toxicity. Acute GVHD was classified as grade 0, I, II, III, or IV according to established criteria [16]. The probability of acute GVHD, nonrelapse mortality rate, overall survival, progression-free survival, and relapse rate were estimated using the Kaplan-Meier method. Death without acute GVHD was treated as censoring in the analysis of acute GVHD, and death without progression was treated as censoring in the analysis of relapse. Dichotomous variables between groups were compared using the χ^2 test, and survival times were compared using the log-rank test. An order-restricted version of the log-rank test (a log-rank trend test) was used to test ordered differences between the estimated survival curves. Multivariate analyses were performed using a logistic regression model or a Cox proportional hazards model, as appropriate. The following covariates were included in the univariate analysis: BMI (BMI < 18 kg/m^2, 18 ≤ BMI < 25 kg/m^2, 25 ≤ BMI < 30 kg/m^2, and 30 kg/m^2 ≤ BMI), sex (donor–recipient pairs), patient age (age < 30 years, 30 ≤ age < 50 years, age ≥ 50 years), donor age (age < 40 years, age ≥ 40 years), type of disease, risk of leukemia relapse (standard vs high), conditioning (TBI-based vs non–TBI-based), GVHD prophylaxis (CSP-based vs TAC-based), genotypic HLA match versus HLA mismatch, ABO match versus mismatch (major mismatch vs minor mismatch vs major/minor mismatch vs match), cell dose in the graft (dose < 3.0 × 10^8/kg, 3.0 ≤ dose < 5.0 × 10^8/kg, ≥ 5.0 × 10^8/kg), and use of ATG/antilymphocyte globulin (ALG) (ATG/ALG vs no ATG/ALG). All P values were 2-sided. A P value < .05 was considered statistically significant.

RESULTS

Patient Characteristics

Table 1 gives the BMI distribution of the study group. Patients were classified into 4 groups based on pretransplantation BMI values according to consensus weight designations from the World Health Organization [17] and the National Heart Lung and Blood Institute Expert Panel [18], as follows: low BMI (BMI < 18 kg/m^2; n = 295), normal BMI (18 ≤ BMI < 25 kg/m^2; n = 2906), overweight (25 ≤ BMI < 30 kg/m^2; n = 565), and obesity (30 kg/m^2 ≤ BMI; n = 61). The prevalence of obesity was quite low compared with that in previous reports from Western countries [1-4]. Significant differences in patient characteristics were observed with regard to age, sex disparity, total nucleated cells (TNCs) per body weight, and primary disease. The low-BMI group

Table 1. **Patient Characteristics**

	n (%)				
	BMI < 18 kg/m²	18 ≤ BMI <25 kg/m²	25 ≤ BMI < 30 kg/m²	30 kg/m² ≤ BMI	
	(n = 295)	(n = 2906)	(n = 565)	(n = 61)	P value
Recipient age, years					
< 30	116 (39)	734 (25)	90 (16)	14 (23)	< .0001
30 ≤ age < 50	121 (41)	1473 (51)	322 (57)	36 (59)	
> 50	58 (20)	699 (24)	153 (27)	11 (18)	
Donor age, years					
< 40	217 (74)	2099 (72)	385 (68)	38 (62)	.27
≥ 40	75 (25)	741 (25)	162 (29)	18 (30)	
Sex, donor/recipient					
Match	181 (61)	1833 (63)	374 (66)	39 (64)	< .0001
Male/female	70 (24)	519 (18)	87 (15)	9 (15)	
Female/male	43 (16)	495 (17)	87 (15)	9 (15)	
TNC (× 10^{-8}/kg)					
TNC < 3.0	12 (4)	323 (11)	160 (28)	31 (51)	< .0001
3.0 ≤ TNC< 5.0	60 (20)	1085 (37)	267 (47)	16 (26)	
5.0 ≤ TNC	187 (63)	1191 (41)	78 (14)	1 (2)	
Year of transplantation					
1998	12 (4)	83 (3)	11 (2)	0 (0)	.18
1999	21 (7)	248 (9)	39 (7)	0 (0)	
2000	26 (9)	363 (12)	81 (14)	7 (11)	
2001	43 (15)	398 (14)	74 (13)	7 (11)	
2002	47 (16)	409 (14)	72 (13)	14 (23)	
2003	50 (17)	404 (14)	87 (15)	10 (16)	
2004	40 (14)	463 (16)	88 (16)	12 (20)	
2005	56 (19)	538 (19)	113 (20)	11 (18)	
Diagnosis					
Acute leukemia	186 (63)	1469 (51)	304 (54)	29 (48)	.02
CR1/CR2/>CR2	81/33/65	594/301/541	113/79/107	7/4/18	
Chronic leukemia	30 (10)	449 (15)	84 (15)	13 (21)	
CP1/CP2/AP/BC	16/5/5/3	251/66/65/53	53/8/12/11	5/3/3/2	
MDS/MPD	37 (13)	462 (16)	87 (15)	11 (18)	
RA/RAEB/others	7/12/10	99/155/166	25/33/20	7/3/1	
ML	35 (12)	400 (14)	62 (11)	4 (7)	
CR/>CR	10/19	138/230	24/33	1/3	
MM	5 (2)	56 (2)	10 (2)	0 (0)	
CR/>CR	1/1	10/33	1/7	0/0	
Disease stage*					
Standard	110 (37)	1034 (36)	202 (36)	19 (31)	.67
High	158 (54)	1686 (58)	324 (57)	38 (62)	
Blood type disparity					
Match	146 (49)	1477 (51)	276 (49)	28 (46)	.98
IA	8 (3)	103 (4)	18 (3)	2 (3)	
MA	71 (24)	650 (22)	127 (22)	13 (21)	
MI	65 (22)	586 (20)	121 (21)	14 (23)	
HLA disparity					
HLA allele match	185 (63)	1660 (57)	342 (61)	36 (59)	.01
HLA allele mismatch	70 (24)	857 (29)	149 (26)	18 (30)	
1 allele mismatch	59 (20)	728 (25)	118 (21)	11 (18)	
2 allele mismatch	10 (3)	116 (4)	31 (5)	6 (10)	
3 allele mismatch	1 (0)	13 (0)	0 (0)	1 (2)	
Conditioning regimen					
Conventional	235 (80)	2308 (79)	443 (78)	52 (85)	.25
Reduced-intensity	59 (20)	539 (19)	105 (19)	5 (8)	
TBI for conditioning					
No	80 (27)	654 (23)	146 (26)	12 (20)	.14
Yes	214 (73)	2188 (75)	402 (71)	45 (74)	
ATG for conditioning					
No	268 (91)	2670 (92)	517 (92)	55 (90)	.21
Yes	23 (8)	155 (5)	25 (4)	2 (3)	
GVHD prophylaxis					
CSP-based	137 (46)	1141 (39)	226 (40)	16 (26)	.19
TAC-based	153 (52)	1651 (57)	312 (55)	39 (64)	
Others	3 (1)	48 (2)	7 (1)	2 (3)	
Comorbidity					
Liver dysfunction					
No	239 (81)	2436 (84)	481 (85)	49 (80)	.78
Yes	41 (14)	360 (12)	66 (12)	7 (11)	

(Continued)

Table I. (Continued)

	n (%)				
	BMI < 18 kg/m²	18 ≤ BMI <25 kg/m²	25 ≤ BMI < 30 kg/m²	30 kg/m² ≤ BMI	
	(n = 295)	(n = 2906)	(n = 565)	(n = 61)	P value
Renal dysfunction					
No	273 (93)	2706 (93)	528 (93)	54 (89)	.90
Yes	7 (2)	90 (3)	19 (3)	2 (3)	
Heart dysfunction					
No	260 (88)	2601 (90)	519 (92)	54 (89)	.32
Yes	20 (7)	195 (7)	28 (5)	2 (3)	
Pulmonary dysfunction					
No	267 (91)	2709 (93)	528 (93)	56 (92)	.27
Yes	13 (4)	87 (3)	19 (3)	0 (0)	

*Disease stage: Standard risk stage included CR I in acute leukemia, first chronic phase in CML, and CR I in lymphoma. Others were classified as high-risk stage.

included more young patients, patients receiving high TNCs per body weight, patients with acute leukemia, and male patients with a female donor.

Clinical Outcomes

The incidence of grade II-IV acute GVHD was 42% in the low-BMI group, 45% in the normal-BMI group, 48% in the overweight group, and 58% in the obesity group (Figure 1A). Thus, increased BMI was significantly associated with a higher incidence of grade II-IV acute GVHD (P = .03 by the log-rank trend test). Other factors associated with a higher incidence of grade II-IV acute GVHD were HLA allele disparity, GVHD prophylaxis with CSP (vs with TAC), and donor age ≥ 40 years. Multivariate analysis showed that pretransplantation BMI tended to be associated with an increased risk of grade II-IV acute GVHD (P = .07, log-rank trend test) (Table 2). The incidence of grade III-IV acute GVHD was 17% in the low-BMI group, 17% in the normal-BMI group, 19% in the overweight group, and 25% in the obesity group (Figure 1B). An increase in BMI tended to be associated with a higher incidence of grade III-IV acute GVHD, but this trend was not significant (P = .087, log-rank trend test). Multivariate analysis showed no association between pretransplantation BMI and the incidence of grade III-IV acute GVHD (P = .19, log-rank trend test) (Table 3).

Nonrelapse mortality was 29% in the low-BMI group, 31% in the normal-BMI group, 32% in the overweight group, and 40% in the obesity group at 1 year after BMT (P = .19, log-rank trend test) (Figure 2A). Overall survival was 61% in the low-BMI group, 58% in the normal-BMI group, 59% in the overweight group, and 53% in the obesity group at 1 year after BMT (P = .98, log-rank trend test) (Figure 2B). Progression-free survival was 54%, 52%, 56%, and 47% (P = .72, log-rank trend test),

and the relapse rate was 24%, 24%, 18%, 21%, respectively, in the 4 groups at 1 year after BMT (P = .04 by log-rank trend test) (Figure 2C and D). The incidence of systemic infectious diseases, including bacterial, fungal, and viral infections, was 39%, 43%, 46%, and 59%, respectively, in the 4 groups (Figure 3). Obesity was significantly associated with increased incidence of infectious disease compared with normal


Figure 1. Probability of grade II-IV acute GVHD (A) and grade III-IV acute GVHD (B).

Table 2. Univariate and Multivariate Analyses of Risk Factors for Grade II-IV Acute GVHD

Covariates	Univariate Analysis			Multivariate Analysis		
	HR	95% CI	P value	HR	95% CI	P value
Recipient BMI						
$18 \leq BMI < 25$ kg/m^2	1.00		.026*	1.00		.066*
BMI < 18 kg/m^2	0.91	0.75 to 1.10		1.06	0.85 to 1.31	
$25 \leq BMI < 30$ kg/m^2	1.11	0.97 to 1.27		1.19	0.93 to 1.52	
$30 \leq BMI$ kg/m^2	1.28	0.89 to 1.85		1.29	0.82 to 2.03	
Recipient age, years						
<30	1.00		.85*			
$30 \leq$ age < 50	1.00	0.88 to 1.13				
≥ 50	0.99	0.86 to 1.14				
Donor age, years						
< 40	1.00		< .0001	1.00		< .0001
≥ 40	1.30	1.17 to 1.45		1.28	1.13 to 1.44	
Sex, donor/recipient						
Match	1.00		.053	1.00		.20
Male/female	1.12	0.98 to 1.27		1.09	0.95 to 1.26	
Female/male	1.15	1.01 to 1.32		1.12	0.97 to 1.30	
TNC ($\times 10^{-8}$/kg)						
TNC <3.0	1.00		.76*			
$3.0 \leq TNC < 5.0$	1.03	0.88 to 1.20				
$5.0 \leq TNC$	0.99	0.85 to 1.16				
Diagnosis						
Acute	1.00		.28			
Chronic	1.08	0.93 to 1.24				
MDS/MPD	1.01	0.87 to 1.16				
ML	1.17	1.01 to 1.35				
MM	0.92	0.62 to 1.36				
Blood type disparity						
M	1.00		.15	1.00		.49
IA	1.19	0.92 to 1.55		1.14	0.85 to 1.52	
MA	1.03	0.90 to 1.16		1.02	0.89 to 1.17	
MI	1.14	1.00 to 1.29		1.11	0.96 to 1.27	
HLA disparity						
HLA allele match	1.00		< .0001	1.00		< .0001
HLA 1 allele mismatch	1.30	1.16 to 1.47		1.36	1.21 to 1.54	
HLA 2 allele mismatch	1.49	1.18 to 1.88		1.51	1.19 to 1.93	
HLA 3 allele mismatch	2.23	1.16 to 4.30		2.23	1.15 to 4.31	
Conditioning regimen:						
TBI for conditioning						
No	1.00		.67			
Yes	0.98	0.87 to 1.10				
Intensity of conditioning:						
Conventional	1.00		.42			
Reduced-intensity	0.95	0.84 to 1.08				
ATG for conditioning						
No	1.00		.58			
Yes	0.94	0.75 to 1.17				
GVHD prophylaxis						
CSP-based	1.00		.025	1.00		.0003
TAC-based	0.89	0.80 to 0.98		0.80	0.71 to 0.89	
Others	1.21	0.84 to 1.75		0.99	0.66 to 1.49	
Comorbidity						
Liver dysfunction						
No	1.00		.52			
Yes	0.95	0.82 to 1.11				
Renal dysfunction						
No	1.00		.84			
Yes	1.03	0.77 to 1.38				
Heart dysfunction						
No	1.00		.58			
Yes	0.94	0.77 to 1.16				
Lung dysfunction						
No	1.00		.15	1.00		.09
Yes	1.22	0.93 to 1.60		1.29	0.96 to 1.74	

*The log-rank trend test was used for calculating P values.

Table 3. Univariate and Multivariate Analyses of Risk Factors for Grade III-IV Acute GVHD

Covariate	Univariate Analysis			Multivariate Analysis		
	HR	95% CI	P value	HR	95% CI	P value
Recipient BMI						
$18 \leq BMI < 25$ kg/m^2	1.00		.086*	1.00		.19*
BMI < 18 kg/m^2	0.99	0.73 to 1.35		1.01	0.72 to 1.43	
$25 \leq BMI < 30$ kg/m^2	1.16	0.94 to 1.45		1.16	0.79 to 1.72	
$30 \leq BMI$ kg/m^2	1.56	0.90 to 2.71		1.42	0.70 to 2.87	
Recipient age, years						
< 30	1.00		.97*			
$30 \leq age < 50$	0.98	0.81 to 1.19				
≥ 50	1.00	0.79 to 1.25				
Donor age, years						
< 40	1.00		< .0001	1.00		< .0001
≥ 40	1.52	1.28 to 1.79		1.53	1.27 to 1.84	
Sex, donor/recipient						
Match	1.00		.057	1.00		.15
Male/female	1.21	0.99 to 1.49		1.13	0.90 to 1.42	
Female/male	1.23	1.00 to 1.51		1.24	0.99 to 1.56	
TNC ($\times 10^{-8}$/kg)						
TNC < 3.0	1.00		.56*			
3.0 < TNC < 5.0	0.90	0.71 to 1.15				
5.0 < TNC	0.91	0.72 to 1.16				
Diagnosis						
Acute leukemia	1.00		.66			
Chronic leukemia	1.13	0.90 to 1.41				
MDS/MPD	0.99	0.78 to 1.24				
ML	0.98	0.77 to 1.26				
MM	0.71	0.35 to 1.43				
Blood type disparity						
M	1.00		.55			
IA	1.04	0.67 to 1.61				
MA	1.11	0.91 to 1.13				
MI	1.15	0.94 to 1.40				
HLA disparity						
HLA allele match	1.00		.0002	1.00		< .0001
HLA 1 allele mismatch	1.36	1.13 to 1.64		1.43	1.18 to 1.74	
HLA 2 allele mismatch	1.57	1.10 to 2.24		1.57	1.07 to 2.30	
HLA 3 allele mismatch	1.49	0.48 to 4.66		1.47	0.47 to 4.60	
Conditioning regimen						
TBI for conditioning						
No	1.00		.49			
Yes	0.94	0.78 to 1.13				
Intensity of conditioning regimen						
Conventional	1.00		.29			
Reduced-intensity	1.11	0.91 to 1.36				
ATG for conditioning						
No	1.00		.26			
Yes	0.80	0.55 to 1.18				
GVHD prophylaxis						
CSP-based	1.00		.029	1.00		.02
TAC-based	0.93	0.79 to 1.10		0.81	0.67 to 0.97	
Others	1.78	1.09 to 2.91		1.27	0.71 to 2.28	
Comorbidity						
Liver dysfunction						
No	1.00		.95			
Yes	0.99	0.78 to 1.27				
Renal dysfunction						
No	1.00		.20			
Yes	1.32	0.87 to 1.99				
Heart dysfunction						
No	1.00		.26			
Yes	0.82	0.57 to 1.16				
Lung dysfunction						
No	1.00		.11	1.00		.20
Yes	1.39	0.93 to 2.07		1.36	0.86 to 2.16	

*The log-rank trend test was used for calculating P values.

Figure 2. Probability of nonrelapse mortality (A), progression-free survival (B), overall survival (C), and relapse/progression (D).

weight (odds ratio = 1.9; 95% confidence interval [CI] = 1.1 to 3.2; P = .02). The incidence of liver dysfunction, including sinusoidal occlusive syndrome, was 19% in the low-BMI group, 20% in the normal-BMI group, 21% in the overweight group, and 25% in the obesity group; the differences were not statistically significant. The incidence of interstitial pneumonia, excluding obvious infectious diseases such as cytomegalovirus or *Pneumocystis jirovecii* pneumonia, was 13% in the low-BMI group, 13% in the normal-BMI group, 12% in the overweight group, and 15% in the obesity group; again, the differences are not statistically significant. The causes of death are given in Table 4. More infections and GVHD-related deaths were seen in the obesity group. If only early mortality is considered, then the nonrelapse mortality within 100 days was 17% in the low-BMI group, 18% in the normal-BMI group, 17% in the overweight group, and 25% in the obesity group. Obesity tended to be associated with greater early nonrelapse mortality, but this difference was not statistically significant (P = .83). The incidence of infection-related mortality within 100 days was 5%, 5%, 4% and 8%, respectively, in the 4 groups. Bacterial infection was the main cause of infection-related mortality, with 6 cases (40%) in the low-BMI group, 91 cases (67%) in the normal-BMI group, 17 cases (74%) in the overweight group, and 3 cases (60%) in the obesity group.

To investigate whether pretransplantation BMI had an additional impact on outcome in the patients who developed acute GVHD, we stratified the patients according to the grade of acute GVHD and analyzed the association between pretransplantation BMI and

early nonrelapse mortality. We found that pretransplantation BMI had no additional impact on early nonrelapse mortality.

DISCUSSION

Both obesity and malnutrition are considered risk factors for complications, especially infectious diseases. To elucidate the impact of pretransplantation BMI on the clinical outcome, in this study we retrospectively reviewed the data of patients who underwent unrelated BMT, stratified according to recipient BMI, and found results similar to those reported previously [1,2]. The present study has an obvious limitation,


Figure 3. Incidence of systemic infections.

Table 4. Causes of Death

	BMI < 18 kg/m^2	18 ≤ BMI < 25 kg/m^2	25 ≤ BMI < 30 kg/m^2	30 kg/m^2 ≤ BMI
	(n = 295)	(n = 2906)	(n = 565)	(n = 61)
Relapse, n (%)	66 (22%)	609 (21%)	95 (17%)	8 (13%)
Nonrelapse mortality, (%)	97 (33%)	988 (34%)	206 (36%)	24 (39%)
Infection, n (%)	25 (8%)	276 (9%)	56 (10%)	8 (13%)
Bacterial, n	13	151	34	4
Fungal, n	3	37	7	1
Viral, n	4	39	5	1
Mixed, n	2	16	3	1
Others, n	3	33	6	1
Acute GVHD, n (%)	9 (3%)	78 (3%)	26 (5%)	4 (7%)
Chronic GVHD, n (%)	4 (1%)	45 (2%)	13 (2%)	2 (3%)
Graft failure, n (%)	2 (1%)	31 (1%)	6 (1%)	1 (2%)
Organ dysfunction, n (%)	47 (16%)	395 (14%)	83 (15%)	7 (11%)
Others, n (%)	10 (3%)	163 (6%)	22 (4%)	2 (3%)

lacking concise data regarding weight-based dose adjustment of chemotherapy, which is critical for analyzing the incidence of organ dysfunction. Dosing schemes for preparative chemotherapy regimens vary widely among transplantation centers. In addition, centers differ in their use of ideal body weight, actual body weight, and compensatory calculations that yield doses between the actual and ideal weights [19,20]. Another limitation of this study is that low prevalence of obesity in Japan makes the study's statistical power less reliable. For example, patients with morbid obesity (BMI > 35 kg/m^2), considered a significant comorbidity in a hematopoietic cell transplantation-specific comorbidity index, are quite rare in Japan [21]. Similar analyses need to be performed in Western countries to clarify the impact of obesity, especially morbid obesity, after allogeneic HSCT.

Our findings demonstrate that obesity is associated with an increased risk of infectious disease compared with normal weight. Hyperglycemia, caused primarily by insulin resistance in obesity, can lead to increased incidence of infectious disease. As reported by Sheean et al. [22], hyperglycemia after HSCT may be a risk factor for infectious disease. Recently, Derr et al. [23] reported an association between hyperglycemia before a neutropenic period and increased risk of infectious diseases during a neutropenic period after HSCT. In our study, an increased incidence of acute GVHD was associated with an increased risk of infectious disease. On the other hand, low BMI, which suggests the presence of malnutrition, was not associated with an increased risk of infectious diseases or transplantation-related mortality, inconsistent with previous reports [10,11]. This could be because the incidence of acute GVHD was lower and the dose of TNC per body weight was higher in the low-BMI group. Even if we further divide the BMI < 18 kg/m^2 group into 3 subgroups (BMI < 16 kg/m^2, 16 ≤ BMI < 17 kg/m^2, and 17 ≤ BMI < 18 kg/m^2), we find no differences in the incidence of acute GVHD or infectious disease, or in clinical outcomes (data

not shown). It is possible that in the Japanese population, BMI < 18 kg/m^2 may not directly reflect a malnutritional status.

Importantly, our findings also suggest an association between increased BMI and a significantly increased incidence of acute GVHD grade II-IV. This observation is based on multiple factors, and no single clear scientific explanation for it exists, but several mechanisms can be hypothesized. First, the dose of the conditioning regimen and GVHD prophylaxis could be improperly adjusted in obese patients, possibly leading to increased tissue damage or poorer GVHD prophylaxis and, ultimately, a higher incidence of acute GVHD. With regard to the conditioning regimen, the relapse rate was lower in the overweight and obese patients compared with the low-BMI and normal-BMI patients, but the incidence of regimen-related toxicity (ie, liver dysfunction and interstitial pneumonitis) did not differ significantly among these groups. With regard to GVHD prophylaxis, there might not have been any significant difference in drug exposure, because dose adjustment of the calcineurin inhibitor usually is done through serial monitoring of drug concentration. Second, the stem cell dose could influence the incidence of acute GVHD. But in this study, the stem cell dose was analyzed independently, and no association was found between stem cell dose and the incidence of acute GVHD. Third, there was an obvious selection bias in each group. For example, it is possible that obese patients may be less likely to find an unrelated donor with an adequate dose of cells for transplantation. While the donor search continued, the number of chemotherapy courses could increase, and the patient's general condition (including disease status and organ function) could become worse. Finally, even though there were no direct data regarding glucose levels in this study, obesity is likely associated with hyperglycemia [7-9], possibly resulting in elevated levels of several cytokines [24-27], inducing a vicious cycle [28-30]. Our group previously reported an association

between hyperglycemia during neutropenia and the development of acute GVHD [6], possibly due to the augmented production of cytokines stimulated by the conditioning regimen. Furthermore, recently it has become clear that adipocytokines, which are secreted mainly from adipocytes, play important roles in the control of immunity [31-33]. In particular, the level of leptin has been found to be proportional to body fat weight and to affect T regulatory cell (Treg) proliferation and function [34,35]. Thus, it could be hypothesized that in obese patients, a higher leptin level suppresses Treg activity, increasing the risk of acute GVHD. These mechanisms are based on the results of animal models, however, and await confirmation in human studies.

The clinical significance of our findings merits careful consideration, because pretransplantation BMI is one of the few factors that can be properly managed and corrected during the unstable, fast-moving pretransplantation period. On the other hand, malnutrition can be corrected by appropriate nutritional support, and obesity can be controlled through an appropriate diet and exercise program during chemotherapy. This study suggests that such a pretransplantation nutritional support program can improve clinical outcomes after allogeneic BMT.

In conclusion, this retrospective analysis of registration data found an association between pretransplantation obesity and increased risk of infectious disease, possibly leading to increased risk of mortality. Although body weight is affected by multiple clinical factors, the effect of obesity on clinical outcome, as suggested here, needs to be confirmed by a prospective study to identify better patient management approaches.

ACKNOWLEDGMENTS

REFERENCES

1. Fleming DR, Rayens MK, Garrison J. Impact of obesity on allogeneic stem cell transplant patients: a matched case-controlled study. *Am J Med.* 1997;102:265-268.

2. Hansen JA, Gooley TA, Martin PJ, et al. Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia. *N Engl J Med.* 1998;338:962-968.

3. Coghlin-Dickson TM, Kusnierz-Glaz CR, Blume KG, et al. Impact of admission body weight and chemotherapy dose adjustment on the outcome of autologous bone marrow transplantation. *Biol Blood Marrow Transplant.* 1999;5:299-305.

4. Meloni G, Proia A, Capria S, et al. Obesity and autologous stem cell transplantation in acute myeloid leukemia. *Bone Marrow Transplant.* 2001;28:365-367.

5. Navarro WH, Loberiza FR Jr., Bajorunaite R, et al. Effect of body mass index on mortality of patients with lymphoma undergoing autologous hematopoietic cell transplantation. *Biol Blood Marrow Transplant.* 2006;12:541-551.

6. Fuji S, Kim SW, Mori S, et al. Hyperglycemia during the neutropenic period is associated with a poor outcome in patients undergoing myeloablative allogeneic hematopoietic stem cell transplantation. *Transplantation.* 2007;84:814-820.

7. Must A, Spadano J, Coakley EH, et al. The disease burden associated with overweight and obesity. *JAMA.* 1999;282: 1523-1529.

8. Rosen ED, Spiegelman BM. Adipocytes as regulators of energy balance and glucose homeostasis. *Nature.* 2006;444:847-853.

9. Hotamisligil GS. Inflammation and metabolic disorders. *Nature.* 2006;444:860-867.

10. Wellen KE, Hotamisligil GS. Inflammation, stress, and diabetes. *J Clin Invest.* 2005;115:1111-1119.

11. Deeg HJ, Seidel K, Bruemmer B, et al. Impact of patient weight on non-relapse mortality after marrow transplantation. *Bone Marrow Transplant.* 1995;15:461-468.

12. Le Blanc K, Ringdén O, Remberger M. A low body mass index is correlated with poor survival after allogeneic stem cell transplantation. *Haematologica.* 2003;88:1044-1052.

13. Schaible UE, Kaufmann SH. Malnutrition and infection: complex mechanisms and global impacts. *PLoS Med.* 2007;4. e115.

14. Sung L, Lange BJ, Gerbing RB, et al. Microbiologically documented infections and infection-related mortality in children with acute myeloid leukemia. *Blood.* 2007;110: 3532-3539.

15. Lange BJ, Gerbing RB, Feusner J, et al. Mortality in overweight and underweight children with acute myeloid leukemia. *JAMA.* 2005;293:203-211.

16. Przepiorka D, Weisdorf D, Martin P, et al. 1994 Consensus Conference on Acute GVHD Grading. *Bone Marrow Transplant.* 1995;15:825-828.

17. Obesity. preventing and managing the global epidemic. Report of a WHO consultation. *World Health Organ Tech Rep Ser.* 2000;894. i-xii,1-253.

18. National Institutes of Health. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: the evidence report. *Obes Res.* 1998;6(Suppl 2). 51S-209S.

19. Tarella C, Cuttica A, Vitolo U, et al. High-dose sequential chemotherapy and peripheral blood progenitor cell autografting in patients with refractory and/or recurrent Hodgkin lymphoma: a multicenter study of the Intergruppo Italiano Linfomi showing prolonged disease-free survival in patients treated at first recurrence. *Cancer.* 2003;97:2748-2759.

20. Navarro WH, Loberiza FR Jr., Bajorunaite R, et al. Effect of body mass index on mortality of patients with lymphoma undergoing autologous hematopoietic cell transplantation. *Biol Blood Marrow Transplant.* 2006;12:541-551.

21. Sorror ML, Maris MB, Storb R, et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. *Blood.* 2005;106: 2912-2919.

22. Sheean PM, Freels SA, Helton WS, et al. Adverse clinical consequences of hyperglycemia from total parenteral nutrition exposure during hematopoietic stem cell transplantation. *Biol Blood Marrow Transplant.* 2006;12:656-664.

23. Derr RL, Hsiao VC, Saudek CD. Antecedent hyperglycemia is associated with an increased risk of neutropenic infections during bone marrow transplantation. *Diabetes Care.* 2008;31: 1972-1977.

24. Cavallo MG, Pozzilli P, Bird C, et al. Cytokines in sera from insulin-dependent diabetic patients at diagnosis. *Clin Exp Immunol.* 1991;86:256-259.

25. Morohoshi M, Fujisawa K, Uchimura I, et al. Glucose-dependent interleukin 6 and tumor necrosis factor production by human peripheral blood monocytes in vitro. *Diabetes.* 1996;45: 954-959.

26. Shanmugam N, Reddy MA, Guha M, et al. High glucose-induced expression of proinflammatory cytokine and chemokine genes in monocytic cells. *Diabetes.* 2003;52:1256-1264.

27. Esposito K, Nappo F, Marfella R, et al. Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans: role of oxidative stress. *Circulation.* 2002;106:2067-2072.

28. Borst SE. The role of TNF-alpha in insulin resistance. *Endocrine.* 2004;23:177-182.

29. Hotamisligil GS, Murray DL, Choy LN, et al. Tumor necrosis factor α inhibits signaling from the insulin receptor. *Proc Natl Acad Sci U S A.* 1994;91:4854-4858.

30. Tsigos C, Papanicolaou DA, Kyrou I, et al. Dose-dependent effects of recombinant human interleukin-6 on glucose regulation. *J Clin Endocrinol Metab.* 1997;82:4167-4170.

31. Lago F, Dieguez C, Gómez-Reino J, et al. Adipokines as emerging mediators of immune response and inflammation. *Nat Clin Pract Rheumatol.* 2007;3:716-724.

32. Tilg H, Moschen AR. Adipocytokines: mediators linking adipose tissue, inflammation and immunity. *Nat Rev Immunol.* 2006;6:772-783.

33. La Cava A, Matarese G. The weight of leptin in immunity. *Nat Rev Immunol.* 2004;4:371-379.

34. Hasenkrug KJ. The leptin connection: regulatory T cells and autoimmunity. *Immunity.* 2007;26:143-145.

35. De Rosa V, Procaccini C, Cali G, et al. A key role of leptin in the control of regulatory T cell proliferation. *Immunity.* 2007;26: 241-255.

ORIGINAL ARTICLE

Intensive glucose control after allogeneic hematopoietic stem cell transplantation: a retrospective matched-cohort study

S Fuji[1], S-W Kim[1], S Mori[1], S Kamiya[2], K Yoshimura[3], H Yokoyama[1], S Kurosawa[1], B Saito[1], T Takahashi[1], S Kuwahara[2], Y Heike[1], R Tanosaki[1], Y Takaue[1] and T Fukuda[1]

[1]Department of Hematology and Stem Cell Transplantation, Tokyo, Japan; [2]Division of Nutritional Management, National Cancer Center Hospital, Tokyo, Japan and [3]Biostatistics and Epidemiology Section, Center for Cancer Control and Information Services, National Cancer Center Hospital, Tokyo, Japan

Some studies have shown that intensive glucose control (IGC) improves outcome in the intensive care unit setting. However, it is the benefit of IGC in hematopoietic SCT (HSCT) that is not well defined. Between June 2006 and May 2007, IGC was maintained prospectively after allogeneic HSCT and clinical outcomes were compared with a cohort matched for conditioning regimen, source of stem cells, age and relation to donor. A stratified Cox regression model was used. There were no significant differences in baseline clinical characteristics. The median age was 43.5 years in both groups. The primary diagnosis was a hematologic malignancy. Patients in the IGC group had a lower glucose level (least-square mean, 116.4 vs 146.8 mg per 100 ml, $P < 0.001$) compared to the standard glucose control group. The incidences of documented infections and bacteremia were significantly lower in the IGC group (14 vs 46%, $P = 0.004$, 9 vs 39%, $P = 0.002$, respectively). IGC tended to reduce the incidence of renal dysfunction (19 vs 37%, $P = 0.36$) and the elevation of C-reactive protein (18 vs 38%, $P = 0.13$). This study suggests that IGC has may have a beneficial effect after HSCT. IGC should be evaluated further in a large prospective, randomized study.
Bone Marrow Transplantation (2009) 44, 105–111; doi:10.1038/bmt.2008.431; published online 19 January 2009
Keywords: intensive glucose control; allogeneic transplantation; hyperglycemia; C-reactive protein

Introduction

Previous studies showed that intensive glucose control (IGC), in which the target blood glucose level was set within 80–110 mg per 100 ml, reduced infections, dysfunction of organs including the liver and kidney and mortality compared to patients who received standard glucose control.[1–3] Although these results have been confirmed in several subsequent studies,[4–7] the precise mechanism that underlies this association is unclear. In animal models, it has been shown that insulin itself has a direct inhibitory effect on the inflammation process.[8,9] However in human studies, it has been suggested that these benefits could be directly attributed to IGC rather than to any pharmacological activity of administered insulin per se.[3,4]

Recipients of allogeneic hematopoietic SCT (HSCT), which is the most drastic therapeutic modality in patients with hematological malignancies, often suffer from serious complications including infectious diseases, GVHD and multiple organ failure. They are also at higher risk of hyperglycemia because of the use of steroids for the treatment of GVHD, the use of total parenteral nutrition (TPN), immunosuppressive drugs and infectious complications,[10,11] which makes them further susceptible to numerous serious complications including infectious diseases and multiple organ failure.[12–14] Our group previously reported that hyperglycemia during neutropenia was associated with an increased risk of acute GVHD and nonrelapse mortality (NRM) after myeloablative allogeneic HSCT,[15] and that hyperglycemia during neutropenia was associated with a higher incidence of subsequent acute GVHD. It is well known that an increase in the levels of circulating cytokines may aggravate hyperglycemia, and hyperglycemia itself could increase the levels of cytokines. This vicious cycle could lead to elevated cytokine levels, which could lead to subsequent acute GVHD. With this background, it can be hypothesized that IGC would reduce the incidence of infectious diseases, acute GVHD and organ dysfunctions after allogeneic HSCT. Therefore, we prospectively investigated the effect of IGC after allogeneic HSCT, and compared the clinical outcomes to those in a matched cohort to address whether IGC following allogeneic HSCT could improve the clinical course of patients, that is, reduction of infectious diseases and organ dysfunction, as has been shown in the intensive care unit (ICU) setting.

Patients and methods

Patients

From June 2006 to May 2007, a total of 73 patients received allogeneic HSCT at the National Cancer Center Hospital (Tokyo, Japan); 60 patients were eligible for participation in this trial. Finally, 22 patients (36.7%) were enrolled in this IGC study to keep the blood glucose level at 80–110 mg per 100 ml, as shown in Figure 1.

Study center and organization

The National Cancer Center Hospital in Tokyo holds 600 beds. The transplant team consists of 4 full-time physicians and 26 nursing staff who oversee 26 beds in the HSCT, and the entire ward is covered by high-efficiency particulate air-filters. We regularly perform 90–120 transplants per year: 80% allogeneic and 20% autologous.

Study design

This was a case–control study to investigate the clinical benefits of comprehensive nutritional support including IGC and parenteral nutrition (PN) management, which was approved by the Institutional Review Board. A matching control group was selected among patients who received HSCT from January 2002 to March 2007 (ratio of 1:2 compared to the study group) according to the following criteria: (1) conditioning regimen (conventional myeloablative or reduced intensity), (2) source of stem cells (BM, peripheral blood or cord blood), (3) age and (4) source of donor (related or unrelated). Criteria (1–4) were essential for inclusion. As a result, 42 matched controls were selected, and a total of 64 patients were subjected to further analysis (Table 1).

Exclusion criteria

Exclusion criteria were as follows: (1) patients who received a reduced-intensity conditioning regimen for an HLA-matched related donor, as we applied GVHD prophylaxis without short-term MTX in this setting, and they had much less need for TPN and less need for intense glucose control,[16] (2) those with a poor performance status (Eastern Cooperative Oncology Group) ≥ 2, (3) those with uncon-

trolled infectious diseases at the beginning of the conditioning regimen and (4) those with preexisting neutropenia. We previously reported that the incidence of severe stomatitis (Common Terminology Criteria for Adverse Events (CTCAE) grade (3) was 0% after reduced-intensity SCT (RIST) from a related HLA-matched donor.[16] In this situation, the need for TPN and the incidence of hyperglycemia were quite low, compared to RIST from an unrelated donor, which included additional low-dose TBI or antithymocyte globulin (ATG) and short-term MTX or conventional SCT with a myeloablative regimen. Hence, we only included patients who received a RIST regimen from an unrelated donor, who had a higher probability of glucose-control intervention, to evaluate the beneficial effects of IGC.

Table 1   Patients' characteristics

Variable	N (%)/median (range)		P-value
	Intensive glucose control (n = 22)	Standard glucose control (n = 42)	
Age (years)	43.5 (17–64)	43.5 (20–66)	
<40	8 (36)	18 (43)	0.62
≥40	14 (64)	24 (57)	
Sex			
Male	9 (41)	22 (52)	0.38
Female	13 (59)	20 (48)	
Disease risk[a]			
Standard	6 (27)	16 (38)	0.39
High	16 (73)	26 (62)	
Conditioning			
CST	14 (64)	27 (64)	
BU/CY	9 (40)	18 (43)	
CY/TBI (12 Gy)	4 (18)	6 (14)	
Other	1 (5)	3 (7)	
RIST	8 (36)	15 (36)	0.96
2CdA/BU	1 (5)	1 (2)	
Flu/BU	7 (32)	14(33)	
Low-dose TBI (2–4 Gy)	3 (14)	7 (17)	
Low-dose ATG	5 (23)	10 (24)	0.92
GVHD prophylaxis			
Cyclosporin-based	7 (32)	27 (64)	
Tacrolimus-based	15 (68)	15 (36)	0.01
Short-term MTX (+)	22 (100)	40 (95)	0.30
Relation to donor			
Related	6 (27)	12 (29)	
Unrelated	16 (73)	30 (71)	0.91
Stem cell source			
Bone marrow	15 (68)	30 (71)	
PBSC	5 (23)	10 (24)	
Cord blood	2 (9)	2 (5)	0.19
HLA match			
Match	11 (50)	28 (67)	
Mismatch	11 (50)	14 (33)	0.19

Abbreviations: ATG = antithymocyte globulin; 2CdA = cladribine; CST = conventional stem cell transplantation; Flu = fludarabine; RIST = reduced-intensity stem cell transplantation.
[a]Standard-risk patients included those with acute leukemia in first complete remission, chronic leukemia in first chronic phase, MDS in refractory anemia and NHL in complete remission, and the remaining patients were categorized as high risk.

Allogenic hematopoietic stem cell transplantation
N=73

Ineligible
N=13

Eligible
N=60

Non-participants
N=38

Participants
N=22

Figure 1   Trial profile.

Transplantation procedures

Forty-one patients received a myeloablative conditioning regimen that included BU (orally 4 mg/kg per day × 4 days or i.v. 3.2 mg/kg per day × 4 days) plus CY (60 mg/kg per day × 2 days, $n = 27$), CY plus 12 Gy TBI ($n = 10$) or other ($n = 4$). Twenty-three patients received a reduced-intensity conditioning regimen that included fludarabine (30 mg/m² per day × 6 days) or cladribine (0.11 mg/kg per day × 6 days) plus BU (oral 4 mg/kg per day × 2 days or i.v. 3.2 mg/ kg per day × 2 days). Low-dose TBI (2 or 4 Gy, $n = 10$) and/or low-dose ATG (total dose 5–10 mg/kg ATG-F or 5 mg/kg thymoglobulin, $n = 15$) were added. GVHD prophylaxis included CYA- ($n = 13$) and tacrolimus-based regimens ($n = 51$), with an additional short course of MTX. G-CSF was administered in all patients from day +6 after transplantation until engraftment. Most patients received ciprofloxacin (200 mg orally three times daily) for bacterial prophylaxis after the beginning of the conditioning regimen until neutrophil engraftment. Fluconazole (100 mg once daily) was administered for fungal prophylaxis after the beginning of the conditioning regimen. Low-dose acyclovir was given for prophylaxis against herpes simplex virus and VZV after the beginning of the conditioning regimen until immunosuppressive agents were discontinued. Prophylaxis against *Pneumocystis jiroveci* infection consisted of tri-methoprim-sulfamethoxazole (400 mg of sulfamethoxazole once daily) from the first day of conditioning to day −3 of transplantation, and from day +28 until day +180 or the cessation of immunosuppressive agents. Patients who developed fever during the neutropenic period were treated with cefepime or other cephalosporin, and additional agents including vancomycin, aminoglycosides and am-photericin B were given as clinically indicated. Neutrophil engraftment was defined as the first of 3 consecutive days after transplantation that the ANC exceeded 0.5×10^9 per l.

Glucose management protocol

In the IGC group, the blood glucose level was routinely tested every morning to adjust the dose of insulin so as to keep the level within the range of 80–110 mg per 100 ml. Owing to the presence of fewer nursing staff in the HSCT unit than in the ICU, we replaced the continuous infusion of insulin with the addition of Humulin R to the bottle of PN to control the glucose level within the target range. In TPN, we universally added at least 1 unit of Humulin R per 10 g glucose. In patients who had an elevated blood glucose level, we also added Humulin R to the bottle of PN. We monitored the glucose level at least once a day in the morning as long as the level remained within the target range of 80–110 mg per 100 ml. When the glucose level became elevated, we increased the frequency of monitoring up to 2–4 times daily. In most patients, we adjusted the dose of insulin added to the bottle of PN as described in Table 2. When the blood glucose level was >180 mg per 100 ml or the dose of insulin was high, we manually adjusted the dose of Humulin R and administered insulin subcutaneously according to the attending physician's discretion. S.c. insulin administration usually consisted of 3–5 units at the beginning, and, if this was insufficient, the dose was manually adjusted by 2–4 units. When the patients received high-dose systemic steroid such as methylpredni-solone 1–2 mg/kg per day for GVHD, we used the preprandial s.c. injection of insulin Aspart (NovoRapid) three times daily to avoid postprandial hyperglycemia and adjusted the dose according to the amount of food intake and the postprandial glucose level. When patients exhibited nausea, anorexia or vomiting, the amount of food intake became unstable. In such situations, insulin Aspart was injected immediately after the meal. When food intake was <50%, the dose was reduced or discontinued. Routine glucose monitoring was continued until PN was stopped, whereas the blood glucose level was maintained within the target range. Daily caloric intake was calculated by the dietitians. We tried to maintain oral intake as much as possible by using a suitable diet in jelly or liquid form. A dietitian adjusted the dose of supplemental PN to maintain the total caloric intake over 1.0 × basal energy expenditure (BEE), and if the glucose level was stable, the nutritional intake could be increased up to 1.5 × BEE. The glucose concentration in PN was usually started at 7.5% glucose as supplemental PN. The concentration was gradually increased to 12%, and, if necessary, this was further increased up to 18% to meet the target caloric intake. A lipid emulsion was also used to supply 10–30% of total caloric intake. The minimal total nutritional intake was set at 1.0 × BEE because a retrospective analysis at our institute showed that caloric intake of more than 1.0 × BEE was not associated with clinically significant wt loss.[17] To improve the glucose control, this level was set to be slightly lower

Table 2 Protocol for adjustment of Humulin R

Glucose level (mg per 100 ml)	Adjustment of Humulin R
BS ≤ 40	i.v. 50% glucose 20 ml and recheck the glucose level Reduce the dose of Humulin R to 40–60% of the original dose
40 ≤ BS < 60	i.v. 50% glucose 20 ml and recheck the glucose level Reduce the dose of Humulin R to 60–80% of the original dose
60 ≤ BS < 80	i.v. 50% glucose 20 ml and recheck the glucose level Reduce the dose of Humulin R to 70–90% of the original dose
80 ≤ BS ≤ 110	No change
110 < BS < 130	Increase the dose of Humulin R to 110–120% of the original dose
130 ≤ BS < 150	Increase the dose of Humulin R to 120–130% of the original dose
150 ≤ BS < 180	Increase the dose of Humulin R to 130–150% of the original dose
BS ≥ 180	Manually adjust the dose of Humulin R combined with sliding subcutaneous insulin administration

Abbreviation: BS = blood sugars.

108

than the recommendation in the HSCT setting (1.3–1.5 ×
BEE[18]). There are two beneficial aspects of this protocol:
we could maintain the minimal caloric intake with
supplemental PN and we could immediately start insulin
as required after the introduction of PN. The SGC group
was managed without a specific protocol for nutrition
practice and glucose control, although we routinely
monitored blood glucose at least three times weekly to
avoid severe hyperglycemia (blood glucose > 200 mg per
100 ml).

Outcome measures

Serially monitored glucose values were compared between
the IGC group and the SGC group. We also analyzed the
association between the mean glucose level during mon-
itoring and the infection rate in both the SGC group and
IGC group. Mean glucose levels were estimated for each
patient and were categorized as follows: 80–110, 111–140,
141–179 and > 180. Glycemic variability, defined as the s.d.
of the mean glucose value, was also analyzed. The outcome
measures were time to the occurrence of documented
infectious complications within 100 days after HSCT, time
to each organ dysfunction defined as described below, time
to grades II–IV and grades III–IV acute GVHD and time
to NRM. These were calculated from the date of the start
of the conditioning regimen. Organ dysfunction was
defined with reference to van den Berghe[5–7] as follows: (1)
hypercreatininemia; serum creatinine level ⩾ 2.0 mg per
100 ml or more than twice the baseline, (2) hyperbilirubi-
nemia; serum total bilirubin level ⩾ 2.0 mg per 100 ml and
(3) increased inflammatory markers; serum C-reactive
protein (CRP) level ⩾ 15 mg per 100 ml. In our institute,
the CRP level was routinely monitored at least three times a
week, as we previously reported that the preengraftment
CRP level may predict a subsequent occurrence of acute
GVHD and NRM after allogeneic HSCT.[19] These results
suggested that CRP might be useful not only as a marker of
infectious diseases but also as a surrogate marker for
produced cytokines. Therefore, the serial changes of CRP
level were compared between the two groups. Acute
GVHD was graded by the consensus criteria.[20]

Statistical analyses

Baseline characteristics were summarized using descriptive
statistics. The Student's t, χ^2 and Wilcoxon rank-sum tests
were used to compare clinical and patient characteristics.
The probability of documented infectious complications
and organ dysfunction were calculated using Kaplan–Meier
estimates. A stratified Cox regression model, which
accounts for the matched-cohort design, was used to
estimate hazard ratios (HRs) and 95% confidence intervals
(CIs). On the basis of 64 patients, the study has an
approximately 80% power to detect a HR of 0.5 for
documented infections. The glucose values, measured
repeatedly, were compared between groups using a
repeated-measure analysis with a linear mixed-effect model.
A level of $P < 0.05$ was defined as statistically significant.
All P-values are two-sided. All analyses were performed
using SAS version 9.1.3 (Cary, NC, USA).

Results

Patient characteristics

Table 1 lists the patients' clinical and transplantation
characteristics. Patients and transplantation characteristics
were well balanced with the application of matching
criteria. Nevertheless, in the IGC group, more patients
received tacrolimus for GVHD prophylaxis (68 vs 36%,
$P = 0.01$) and more had a previous transplantation (32 vs
7%, $P = 0.01$). The median duration of follow-up in
surviving patients was 299 days (range, 78–607 days) in
the IGC group and 1146 days (range, 329–1774 days) in the
SGC group.

Glycemic control

Duration of monitoring and number of tests. The median
duration of glucose monitoring and intervention in the IGC
group was 38 days (range, 24–70 days) after the start of the
conditioning regimen. The total number of glycemic
monitorings was 867 and 1094 in the SGC group and
IGC group, respectively.

Mean values and distribution of values. Patients in the IGC
group had a lower glucose level (least-square mean, 116.4
vs 146.8 mg per 100 ml, $P < 0.001$) than the SGC group.
The trend of the glucose value is shown in Figure 2a.
All glycemic results for the SGC and IGC groups were
stratified into six levels: < 40, 40–79, 80–110, 111–140, 141–
179 and ⩾ 180, as shown in Figure 2b.

Hypoglycemia

In the IGC group, the incidence of mild hypoglycemia
(CTCAE grades 1–2, glucose level 40–69 mg per 100 ml)
was significantly higher than that in the SGC group (11 vs 3
patients, $P < 0.001$). Although one patient (4.5%) in the
IGC group who was diagnosed as type 2 diabetes mellitus
developed severe hypoglycemia (CTCAE grade 3, glucose
level 30–39 mg per 100 ml) with faintness, no patient
developed seizure or loss of consciousness.

Glycemic variability

The mean glycemic variability in the SGC group and IGC
group was 37.2 mg per 100 ml (range, 10.1–121.7 mg per
100 ml) and 27.5 mg per 100 ml (range, 11.3–46.6 mg per
100 ml), respectively, and glycemic variability in the IGC
group tended to be lower than that in the SGC group
($P = 0.07$).

TPN and insulin dosing

The percentage of patients who received TPN was 60% (25
patients) and 77% (17 patients) in the SGC group and the
IGC group, respectively. The mean duration of TPN was 9
days (range, 0–35) and 13 days (range, 0–38) in the SGC
group and IGC group, respectively. There was a tendency
for more patients in the IGC group to receive TPN
compared to the SGC group, but this difference was not
statistically significant. The mean maximal dose of insulin
(median (range), 51 (0–100) vs 2 (0–110) IU, $P < 0.001$) and
the mean maximal dose of insulin per 1 g parenteral glucose

were significantly higher in the IGC group (median (range), 0.22 (0–0.71) vs 0.003 (0–0.4) IU/g glucose, $P < 0.001$).

Infections

Table 3 summarizes the results. In the IGC group, dramatically fewer patients developed documented infec-

a

b

Figure 2 Serial changes in the mean glucose level in the intensive glucose control (IGC) and standard glucose control (SGC) groups. Values are mean + s.e. (a). The distribution of the glucose values in IGC and SGC is shown as a histogram (b).

tions within 100 days compared to the SGC group, as shown in Figure 3.

Relation to mean glucose level

We also analyzed the association between the mean glucose level during monitoring and the infection rate in both the SGC and IGC groups. The incidence of infection was 34, 17, 67 and 40%, respectively, with mean glucose levels of 80–110, 111–140, 141–179 and $\geqslant 180$. When we compared a lower glucose-level group (mean glucose level of 80–140) with a higher glucose-level group (mean glucose level of > 140), the incidence of infection was significantly higher in the latter group (28 vs 57%, $P = 0.042$). When we assessed only patients with a lower glucose level, the IGC group tended to show a lower incidence of infectious diseases than the SGC group (14 vs 41%, $P = 0.061$).

Relation to glycemic variability

We also analyzed the association between glycemic variability and the infection rate. The mean glycemic variability in patients with and without infection was 34.6 mg per 100 ml (range, 10.5–121.7 mg per 100 ml) and 33.3 mg per 100 ml (range, 10.1–110.6 mg per 100 ml), respectively, with no significant difference. As the importance of glycemic variability could vary among patients

Figure 3 Probability of documented infections in the IGC and SGC groups.

Table 3 Incidence of infectious diseases and organ dysfunction

Variable	N (%)/median (range)			
	Intensive glucose control n = 22 (%)	Standard glucose control n = 42 (%)	HR (95% CI)	P-value
Documented infection	13	46	0.17 (0.04–0.75)	0.004
Bacteremia	9	39	0.10 (0.01–0.74)	0.002
Organ dysfunction				
Hypercreatininemia[a]	19	37	0.60 (0.19–1.88)	0.36
Hyperbilirubinemia[b]	28	31	1.05 (0.38–2.91)	0.93
Increased inflammatory markers[c]	18	38	0.45 (0.15–1.37)	0.13

Abbreviations: CI = confidence interval.
[a]Serum creatinine level $\geqslant 2.0$ mg per 100 ml or more than twice of baseline.
[b]Serum bilirubin level $\geqslant 2.0$ mg per 100 ml.
[c]Serum C-reactive protein level $\geqslant 15$ mg per 100 ml.

110

with different mean glucose levels,[21] we divided the patients into two groups based on mean glucose level 80–140 or 140+ and then determined whether glycemic variability was associated with an increased incidence of infections. However, there was no significant association between glycemic variability and the incidence of infections in both groups.

CRP levels

Figure 4 shows serial changes in the CRP level. Even though there was no difference in the CRP level between the two groups at the beginning of the conditioning regimen, the CRP level was significantly elevated in the SGC group compared to that in the IGC group 15 days after the beginning of the conditioning regimen, and this trend continued up to 40 days ($P < 0.05$). The maximal CRP level during the neutropenic period in the IGC group was significantly lower than that in the SGC group (median (range), 6.9 (0.9–16.3) vs 11.5 (1.6–37.3), $P = 0.007$).

Other clinical outcomes

The probability of grades II–IV acute GVHD within 100 days was 28 and 37% in the IGC and SGC groups (HR 1.05, 95% CI 0.38–2.91, $P = 0.93$). The incidences of grades III–IV acute GVHD and NRM within 100 days were low in both groups (one and two patients, and one and one patient, in the IGC and SGC groups, respectively).

Discussion

This is the first study to evaluate the outcomes in allogeneic HSCT patients who were treated with a glucose management protocol. A salient finding of this study is that the incidence of documented infections, especially the incidence of bacteremia, was significantly lower in the IGC group than in the SGC group, as in a previous report in the ICU setting.[1] Moreover, there tended to be fewer organ dysfunctions in the IGC group, albeit this difference was not statistically significant. Furthermore, the CRP level,

which might be a surrogate marker for produced cytokines,[19] was significantly lower in the IGC group than in the SGC group, as shown in Figure 4. Even though this study did not have enough power to detect a decrease in acute GVHD and NRM, it could be anticipated that IGC could reduce the CRP level, which would lead to a reduced incidence of acute GVHD and NRM.

This study has several limitations. One limitation is that only 64 patients were analyzed with no sufficient power to demonstrate any statistically significant changes in the incidences of organ dysfunctions, which was similar to the result in a previous report in the ICU.[1,2] An additional limitation was that the control of the glucose level could be suboptimal. This could be because of the glucose control protocol, which included monitoring of glucose level and the administration of insulin. With regard to the administration of insulin, we replaced the continuous infusion of insulin with the addition of Humulin R to the bottle of PN to control the glucose level within the target range because of the presence of fewer nursing staff in the HSCT unit than in the ICU. This could delay the normalization of hyperglycemia. Even though severe hyperglycemia (>180 mg per 100 ml) was reduced, a glucose value within the normal range (80–110 mg per 100 ml) could be achieved in only 49% of the IGC group as shown in Figure 1b. From a methodological point of view, it might be inappropriate to simply count the number of glucose value measurements, as patients with hyperglycemia were monitored more frequently, as defined in this protocol. Furthermore, as the mode of glucose monitoring was quite different between the IGC group and the SGC group, it could be inappropriate to compare the glucose values. A future protocol should include a more appropriate monitoring of glucose level and administration of insulin system that assures the fine tuning of glucose levels within the target range. Finally, there was a possible selection bias that may have affected the results, as this study was not a randomized-control study and there were many nonparticipants. However, the incidence of documented infections in nonparticipants within 100 days after allogeneic HSCT was 42%. Therefore, the reduction in the incidence of documented infections in the IGC group could not simply be explained by other causes such as the selection of antibiotics or catheter management.

With these limitations in mind, we took several steps to improve the quality of the study. First, we carefully matched patients and transplantation characteristics. Second, the IGC strategy was applied prospectively. Third, the low rate of patients who developed clinically significant hypoglycemia should be emphasized. As previously reported, the IGC procedure becomes very difficult in the medical ICU, especially in patients who have sepsis, a high APACHE score or mechanical ventilation.[1,2,22,23] The low rate of hypoglycemia could be because the medical acuity of our patients were relatively mild compared to those of patients in the medical ICU. Moreover, patients undergoing HSCT are younger and might have better β-cell function. The low rate of hypoglycemia could be important for maximizing the benefit of IGC because severe hypoglycemia could be associated with an increased risk of mortality.[23]


(mg per 100 ml)

Figure 4 Serial change in the CRP level in the IGC and SGC groups. Values are mean + s.e.

The biological plausibility of the intervention should be discussed. The reduction in infectious diseases by IGC may reflect the deleterious effects of hyperglycemia on macrophage or neutrophil function or insulin-induced protective effects on mucosal and skin barriers.[24-27] The improvement of innate immunity could be quite important, especially during the period of granulocytopenia after allogeneic HSCT. The protection of mucosal tissues could reduce bacterial translocation, which might lead to a reduced incidence of sepsis.

In conclusion, our results suggest that prospective IGC reduced the incidences of infectious diseases and organ dysfunction after allogeneic HSCT. To confirm these findings, a larger, prospective randomized-controlled trial is warranted.

Acknowledgements

References

1 Van den Berghe G, Wouters P, Weekwrs F, Verwaest C, Bruyninckx F, Schetz M et al. Intensive insulin therapy in the critically ill patients. N Engl J Med 2001; 345: 1359–1367.

2 Van den Berghe G, Wilmer A, Hermans G, Meersseman W, Wouters PJ, Milants I et al. Intensive insulin therapy in the medical ICU. N Engl J Med 2006; 354: 449–461.

3 Van den Berghe G, Wouters PJ, Bouillon R, Weekers F, Verwaest C, Schetz M et al. Outcome benefit of intensive insulin therapy in the critically ill: insulin dose versus glycemic control. Crit Care Med 2003; 31: 359–366.

4 Krinsley JS. Association between hyperglycemia and increased hospital mortality in a heterogeneous population of critically ill patients. Mayo Clin Proc 2003; 78: 1471–1478.

5 Krinsley JS. Effect of an intensive glucose management protocol on the mortality of critically ill adult patients. Mayo Clin Proc 2004; 79: 992–1000.

6 Vogelzang M, Nijboer JM, van der Horst IC, Zijlstra F, ten Duis HJ, Nijsten MW. Hyperglycemia has a stronger relation with outcome in trauma patients than in other critically ill patients. J Traum 2006; 60: 873–877.

7 Ingels C, Debaveye Y, Milants I, Buelens E, Peeraer A, Devriendt Y et al. Strict blood glucose control with insulin during intensive care after cardiac surgery: impact on 4-years survival, dependency on medical care, and quality-of-life. Eur Heart J 2006; 27: 2716–2724.

8 Jeschke MG, Klein D, Bolder U, Einspanier R. Insulin attenuates the systemic inflammatory response in endotoxemic rats. Endocrinology 2004; 145: 4084–4093.

9 Brix-Christensen V, Andersen SK, Andersen R, Mengel A, Dyhr T, Andersen NT et al. Acute hyperinsulinemia restrains endotoxin-induced systemic inflammatory response: an experimental study in a porcine model. Anesthesiology 2004; 100: 861–870.

10 Sheean PM, Freels SA, Helton WS, Braunschweig CA. Adverse clinical consequences of hyperglycemia from total parenteral nutrition exposure during hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2006; 12: 656–664.

11 Sheean PM, Braunschweig C, Rich E. The incidence of hyperglycemia in hematopoietic stem cell transplant recipients receiving total parenteral nutrition: a pilot study. J Am Diet Assoc 2004; 104: 1352–1360.

12 Fietsam Jr R, Bassett J, Glover JL. Complications of coronary artery surgery in diabetic patients. Am Surg 1991; 57: 551–557.

13 Ortiz A, Ziyadeh FN, Neilson EG. Expression of apoptosis-regulatory genes in renal proximal tubular epithelial cells exposed to high ambient glucose and in diabetic kidney. J Invest Med 1997; 45: 50–56.

14 Vanhorebeek I, De Vos R, Mesotten D, Wouters PJ, De Wolf-Peeters C, Van den Berghe G. Protection of hepatocyte mitochondrial ultrastructure and function by strict blood glucose control with insulin in critically ill patients. Lancet 2005; 365: 53–59.

15 Fuji S, Kim SW, Mori S, Fukuda T, Kamiya S, Yamasaki S et al. Hyperglycemia during the neutropenic period is associated with a poor outcome in patients undergoing myeloablative allogeneic hematopoietic stem cell transplantation. Transplantation 2007; 84: 814–820.

16 Saito AM, Kami M, Mori SI, Kanda Y, Suzuki R, Mineishi S et al. Prospective phase II trial to evaluate the complications and kinetics of chimerism induction following allogeneic hematopoietic stem cell transplantation with fludarabine and busulfan. Am J Hematol 2007; 82: 873–880.

17 Fuji S, Kim S, Fukuda T, Kamiya S, Kuwahara S, Takaue Y. Positive impact of maintaining minimal caloric intake above 1.0 × basal energy expenditure on nutritional status of patients undergoing allogeneic hematopoietic stem cell transplantation. Am J Hematol 2008; 84: 63–64.

18 Muscaritoli M, Grieco G, Capria S, Iori AP, Rossi Fanelli F. Nutritional and metabolic support in patients undergoing bone marrow transplantation. Am J Clin Nutr 2002; 75: 183–190.

19 Fuji S, Kim SW, Fukuda T, Mori S, Yamasaki S, Morita-Hoshi Y et al. Pre-engraftment serum C-reactive protein (CRP) value may predict acute graft-versus-host disease and non-relapse mortality after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2008; 14: 510–517.

20 Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995; 15: 825–828.

21 Ali NA, O'Brien Jr JM, Dungan K, Phillips G, Marsh CB, Lemeshow S et al. Glucose variability and mortality in patients with sepsis. Crit Care Med 2008; 36: 2316–2321.

22 Van Cromphaut S, Wilmer A, Van den Berghe G. Management of sepsis. N Engl J Med 2007; 356: 1179–1181.

23 Krinsley JS, Grover A. Severe hypoglycemia in critically ill patients: risk factors and outcomes. Crit Care Med 2007; 35: 2262–2267.

24 Rayfield EJ, Ault MJ, Keusch GT, Brothers MJ, Nechemias C, Smith H. Infection and diabetes: the case for glucose control. Am J Med 1982; 72: 439–450.

25 Geerlings SE, Hoepelman AI. Immune dysfunction in patients with diabetes mellitus (DM). FEMS Immunol Med Microbiol 1999; 26: 259–265.

26 Rassias AJ, Marrin CA, Arruda J, Whalen PK, Beach M, Yeager MP. Insulin infusion improves neutrophil function in diabetic cardiac surgery patients. Anesth Analg 1999; 88: 1011–1016.

27 Losser MR, Bernard C, Beaudeux JL, Pison C, Payen D. Glucose modulates hemodynamic, metabolic, and inflammatory responses to lipopolysaccharide in rabbits. J Appl Physiol 1997; 83: 1566–1574.